INTRODUCTION: Colorectal cancer is a heterogeneous tumor type with regard to molecular pathogenesis and genetic instability. The majority of colorectal cancers display chromosomal instability and follow the classical adenoma-carcinoma sequence of tumor progression. A subset of about 15 % of colorectal cancers, however, displays DNA mismatch repair (MMR) deficiency and the high-level microsatellite instability (MSI-H) phenotype. MSI-H colorectal cancers can occur as sporadic tumors or in the context of hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome. CLINICAL RELEVANCE: The MSI-H phenotype is a hallmark of Lynch syndrome-associated cancers, which is of diagnostic relevance for the identification of Lynch syndrome mutation carriers. MSI-H colorectal cancers are characterized by a distinct clinical behavior, which results from their particular molecular pathogenesis and gives microsatellite instability testing its clinical significance. The MSI-H phenotype shows association with proximal tumor localization, a dense local lymphocyte infiltration, and a low frequency of distant organ metastasis. Moreover, MSI-H colorectal cancers have a better prognosis than their microsatellite-stable counterparts. A distinct responsiveness of MSI-H colorectal cancer patients towards chemotherapy has been shown in several studies. CONCLUSIONS: The clinical characteristics of MSI-H cancers are closely linked to their molecular pathogenesis, and research on the molecular alteration characteristic of MSI-H cancers may provide the basis for novel diagnostic or therapeutic approaches.
INTRODUCTION:Colorectal cancer is a heterogeneous tumor type with regard to molecular pathogenesis and genetic instability. The majority of colorectal cancers display chromosomal instability and follow the classical adenoma-carcinoma sequence of tumor progression. A subset of about 15 % of colorectal cancers, however, displays DNA mismatch repair (MMR) deficiency and the high-level microsatellite instability (MSI-H) phenotype. MSI-H colorectal cancers can occur as sporadic tumors or in the context of hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome. CLINICAL RELEVANCE: The MSI-H phenotype is a hallmark of Lynch syndrome-associated cancers, which is of diagnostic relevance for the identification of Lynch syndrome mutation carriers. MSI-H colorectal cancers are characterized by a distinct clinical behavior, which results from their particular molecular pathogenesis and gives microsatellite instability testing its clinical significance. The MSI-H phenotype shows association with proximal tumor localization, a dense local lymphocyte infiltration, and a low frequency of distant organ metastasis. Moreover, MSI-H colorectal cancers have a better prognosis than their microsatellite-stable counterparts. A distinct responsiveness of MSI-H colorectal cancerpatients towards chemotherapy has been shown in several studies. CONCLUSIONS: The clinical characteristics of MSI-H cancers are closely linked to their molecular pathogenesis, and research on the molecular alteration characteristic of MSI-H cancers may provide the basis for novel diagnostic or therapeutic approaches.
Authors: R Dolcetti; A Viel; C Doglioni; A Russo; M Guidoboni; E Capozzi; N Vecchiato; E Macrì; M Fornasarig; M Boiocchi Journal: Am J Pathol Date: 1999-06 Impact factor: 4.307
Authors: Karen H Lu; Mai Dinh; Wendy Kohlmann; Patrice Watson; Jane Green; Sapna Syngal; Prathap Bandipalliam; Lee-May Chen; Brian Allen; Peggy Conrad; Jonathan Terdiman; Charlotte Sun; Molly Daniels; Thomas Burke; David M Gershenson; Henry Lynch; Patrick Lynch; Russell R Broaddus Journal: Obstet Gynecol Date: 2005-03 Impact factor: 7.661
Authors: Miriam Reuschenbach; Matthias Kloor; Monika Morak; Nicolas Wentzensen; Anja Germann; Yvette Garbe; Mirjam Tariverdian; Peter Findeisen; Michael Neumaier; Elke Holinski-Feder; Magnus von Knebel Doeberitz Journal: Fam Cancer Date: 2010-06 Impact factor: 2.375
Authors: A Buckowitz; H-P Knaebel; A Benner; H Bläker; J Gebert; P Kienle; M von Knebel Doeberitz; M Kloor Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Henry T Lynch; Stephen Lanspa; Trudy Shaw; Murray Joseph Casey; Marc Rendell; Mark Stacey; Theresa Townley; Carrie Snyder; Megan Hitchins; Joan Bailey-Wilson Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: Jinru Shia; Zsofia K Stadler; Martin R Weiser; Efsevia Vakiani; Robin Mendelsohn; Arnold J Markowitz; Moshe Shike; C Richard Boland; David S Klimstra Journal: Fam Cancer Date: 2015-03 Impact factor: 2.375
Authors: L De Smedt; J Lemahieu; S Palmans; O Govaere; T Tousseyn; E Van Cutsem; H Prenen; S Tejpar; M Spaepen; G Matthijs; C Decaestecker; X Moles Lopez; P Demetter; I Salmon; X Sagaert Journal: Br J Cancer Date: 2015-06-11 Impact factor: 7.640